Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior weight loss (up to -20.9% at 15mg) compared to placebo and established GLP-1 agonists, though it is not yet fully approved for obesity treatment in all contexts.
Tirzepatide (5-15 mg weekly) is a powerful dual-action drug that can help you lose up to 21% of your body weight. It is more effective than current GLP-1 drugs like semaglutide. However, it may not be fully approved for obesity treatment in your region yet, so discuss with your doctor if it's an option for you.
Tirzepatide demonstrated an even more relevant result, but its use is still not approved for obesity treatment due to the necessity of more trials testing the drug for this purpose.
Why this rating
Based on the SURMOUNT-1 RCT included in the review.
Source
O USO DE ANÁLOGOS DE GLP-1 LIRAGLUTIDA, SEMAGLUTIDA E TIRZEPATIDA NO TRATAMENTO DA OBESIDADE: UMA REVISÃO DE LITERATURA
Bruna Machado Staico et al. · RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218 · 2023
DOI 10.47820/recima21.v4i4.2950
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →